Hepatitis C virus (HCV) exhibits a high level of genetic variability, and variants with reduced susceptibility to antivirals can occur even before treatment begins. In addition, alcohol decreases efficacy of antiviral therapy and increases sequence heterogeneity of HCV RNA but how ethanol affects HCV sequence is unknown. Ethanol metabolism and HCV infection increase the level of reactive species that can alter cell metabolism, modify signaling, and potentially act as mutagen to the viral RNA. Therefore, we investigated whether ethanol and reactive species affected the basal sequence variability of HCV RNA in hepatocytes. Human hepatoma cells supporting a continuous replication of genotype 1b HCV RNA (Con1, AJ242652) were exposed to ethanol, acetaldehyde, hydrogen peroxide, or L-buthionine-S,R-sulfoximine (BSO) that decreases intracellular glutathione as seen in patients. Then, NS5A region was sequenced and compared with genotype 1b HCV sequences in the database. Ethanol and BSO elevated nucleotide and amino acid substitution rates of HCV RNA by 4–18 folds within 48 hrs which were accompanied by oxidative RNA damage. Iron chelator and glutathione ester decreased both RNA damage and mutation rates. Furthermore, infectious HCV and HCV core gene were sufficient to induce oxidative RNA damage even in the absence of ethanol or BSO. Interestingly, the dn/ds ratio and percentage of sites undergoing positive selection increased with ethanol and BSO, resulting in an increased detection of NS5A variants with reduced susceptibility to interferon alpha, cyclosporine, and ribavirin and others implicated in immune tolerance and modulation of viral replication. Therefore, alcohol is likely to synergize with virus-induced oxidative/nitrosative stress to modulate the basal mutation rate of HCV. Positive selection induced by alcohol and reactive species may contribute to antiviral resistance.
Citation: Seronello S, Montanez J, Presleigh K, Barlow M, Park SB, Choi J (2011) Ethanol and Reactive Species Increase Basal Sequence Heterogeneity of Hepatitis C Virus and Produce Variants with Reduced Susceptibility to Antivirals. PLoS ONE 6(11): e27436. https://doi.org/10.1371/journal.pone.0027436
Editor: Jean-Luc E. P. H. Darlix, Institut National de la Santé et de la Recherche Médicale, France
Received: June 1, 2011; Accepted: October 17, 2011; Published: November 8, 2011
Copyright: © 2011 Seronello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by start up funds and faculty research grants to J.C. from UC-Merced and an NIH grant #1R56AI083353-01A1 (http://projectreporter.nih.gov/project_info_details.cfm?aid=8130414&icde=10161487). Partial sequencing was donated by Eddy Rubin, director of the DOE Joint Genome Institute, through the sequencing quota allocated to the UC Merced Genome Biology course (BIS 142) in Spring 2008. The funders had no role in study design, data collection and analysis,decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Hepatitis C virus (HCV) is a major etiologic agent of severe liver diseases including cirrhosis and hepatocellular carcinoma that has infected about 170 million people worldwide. Current anti-HCV therapy, consisting of pegylated interferon alpha and a nucleoside analog, ribavirin, results in sustained virological response in only 50-60% of patients undergoing treatment , . Both the efficacy of antiviral therapy and success of re-treating the resistant population are strongly affected by HCV sequence. Specific HCV factors have also been identified that can affect the sensitivity of the virus to antivirals, such as NS5A , . In addition, HCV, like other RNA viruses, exhibits a high level of genetic variability that complicates antiviral therapy and development of vaccines. HCV variants with reduced susceptibility to antivirals can occur naturally, even before treatment begins . Such pronounced basal sequence heterogeneity and generation of escape mutants remain an ongoing concern even as new antivirals and vaccine candidates are being tested , , . Furthermore, alcohol decreases the efficacy of anti-HCV therapy, and alcohol use is correlated with increased sequence heterogeneity of HCV RNA in patients , . However, how ethanol affects HCV sequences is unclear.
Ethanol metabolism generates acetaldehyde and reactive oxygen species (ROS), reactive nitrogen species (RNS), and lipid peroxidation products while decreasing glutathione (GSH) and selenium . In addition, HCV induces oxidative/nitrosative stress through several mechanisms which is exacerbated by ethanol, and GSH is significantly depleted in hepatitis C patients , . Acetaldehyde, ROS, RNS, and lipid peroxidation products can attack the bases and deoxyribose backbone of the DNA and/or RNA and may thus act as mutagen to the viral RNA , . In addition, evolution is affected by the environment, and ethanol, reactive species, and lipid peroxidation products can also alter the intracellular milieu for viral replication by modification of cell metabolism and signaling which may cause the virus to adapt , .
The goal of this study, therefore, was to test the effects of ethanol and reactive species on the mutability of HCV RNA in hepatocytes. Genotype 1 HCV shows higher resistance to therapy. Thus, Con1 replicon of genotype 1b, which is the best characterized in terms of adaptive mutations and replicative functions, was exposed to physiologically attained and non-cytotoxic concentrations of ethanol and acetaldehyde and then analyzed for mutation trends. L-Buthionine-S,R-sulfoximine (BSO) decreases intracellular GSH by 60–75% in these cells and was also utilized in the study to test the effects of GSH depletion seen in hepatitis C patients , . Exogenous H2O2, on the other hand, was used to observe the effects of sublethal, exogenous oxidative stress . We found that ethanol and reactive species increase oxidative RNA damage and sequence heterogeneity of the HCV RNA with evidence of positive selection. RNA damage, sequence heterogeneity of HCV RNA, and positive selection could be decreased by ROS/RNS-decreasing agents. Mutation trends and possible biological consequences of these mutations are discussed.
Ethanol and reactive species increase the mutation rate of HCV
To determine whether ethanol can affect the sequence variability of HCV RNA, Huh7 cells that support continuous replication of genotype 1b Con1 replicon RNA were incubated with ethanol (0.5% v/v), acetaldehyde (10 µM), bolus H2O2 (100 µM), or BSO (20 µM) once daily for 48 hrs . Then, the RNAs were collected, and the NS5A region was cloned by reverse transcription-polymerase chain reaction, sequenced, and compared against Con1(S1179I) sequence. We focused on NS5A because of its moderate level of diversity and its role in viral replication and antiviral resistance , , , . The T7 HCV RNA transcript, initially used to generate the replicon cells, was also sequenced to assess the basal level of RNA heterogeneity potentially rising from any heterogeneity of HCV DNA used in the in vitro transcription as well as errors generated during transcription and/or cloning. After subtracting the T7 baseline values, the nt. and amino acid substitution rates of control cells were determined to be 2.89×10−4 nt. changes per site and 2.80×10−4 amino acid changes per codon (Table 1). The ethanol group showed a 6 fold increase in the nt. substitution rate and an 18 fold increase in the amino acid substitution rate over the control (P<0.001). The BSO group also displayed a significant increase in the sequence variability of HCV RNA, showing approximately 4 and 12 fold increases in nt. and amino acid substitution rates, respectively (P<0.05). H2O2 and acetaldehyde did not increase the nt. substitution rates significantly (5.28×10−4 and 4.25×10−4 nt. change per site, respectively, P>0.05) but the amino acid substitution rate increased by about 10 fold with H2O2. Therefore, ethanol and conditions that mimic GSH depletion seen in vivo could increase the nt. and amino acid substitution rates of HCV RNA over 48 hr.
Analysis of 1,212 genotype 1b sequences in the HCV sequence database revealed that transitions account for over 83.5% of all nt. substitutions (Table S1) with the Ts/Tv ratio of 5.05. Likewise, transitions comprised the majority of the nucleotide substitutions in our control and treatment groups (Table 1 and Table S1). Ethanol increased transitions more than transversions such that the Ts/Tv ratio rose from 3.3 to 6.8.
Ethanol, reactive species, and oxidative RNA damage
The observation that BSO had a greater effect on the HCV sequence than exogenous H2O2 or acetaldehyde suggested that there was a substantial level of endogenous oxidative/nitrosative stress in these cells and that endogenous ROS/RNS may have a greater effect on the HCV RNA than acetaldehyde. Therefore, to substantiate the presence of oxidative/nitrosative stress and to test the potential role of oxidative RNA damage in the accelerated mutation rate of HCV in ethanol and BSO groups, we measured 8-OHG; 8-OHG is the best-characterized and abundant form of ROS/RNS-generated RNA species , . NiCl2, a positive control mutagen , induced a 55.4±3.1 fold increase in 8-OHG content over the control (P<0.05) (Fig. 1A). In addition, ethanol and BSO increased the level of 8-OHG by 34.9±1.2 and 23.4±1.5 folds, respectively (P<0.05) (Fig. 1A). Therefore, ethanol and reactive species could damage the RNA under the same conditions that elevated the sequence variability of HCV RNA. Daily treatment of the replicon cells with 0.1% ethanol (v/v) or 20 µM BSO for 2 weeks likewise led to significant increases in 8-OHG (Fig. 1B). The 0.1% ethanol is equivalent to blood alcohol concentration of 17.2 mM, which is approximately the legal limit for driving under the influence in many countries.
(A) Con1 replicon cells were incubated with 0.5% (v/v) ethanol, 20 µM BSO, or 250 µM NiCl2 daily for 48 hr and analyzed for 8-OHG by ELISA. (B) Con1 replicon cells were incubated with 0.1% (v/v) ethanol, 20 µM BSO, or 50 µM NiCl2 daily for 2 weeks and analyzed for 8-OHG by ELISA. Data were expressed as fold increase from the controls (0.134±0.013 ng/ml for panel A and 0.418±0.109 ng/ml for panel B). * Indicates statistically significant difference from controls (n = 4 in panel A, n = 6 in panel B).
Then, whether agents that decrease ROS/RNS can reduce the accelerated mutation rate of HCV was tested. As HCV infection is associated with iron overload , cells were incubated with α,α'-dipyridyl, a cell permeable iron chelator, in the presence and absence of ethanol or BSO. Dipyridyl significantly decreased the level of 8-OHG in both ethanol and BSO groups (Fig. 2A). Similarly, GSH ester reduced 8-OHG content in these groups (Fig. 2A). 8-OHG could also be decreased by other iron chelators and inhibitors of nitric oxide synthase, flavoproteins, and CYP2E1 (Fig. S1A). Most of all, dipyridyl decreased the nt. substitution rates of both ethanol and BSO groups so that there was no longer any significant increase over the control (Fig. 2B). The amino acid substitution rate was also significantly attenuated by dipyridyl in these groups (P<0.05) (Fig. 2C). Likewise, GSH ester decreased both nt. and amino acid substitution rates of ethanol and BSO treatment groups (Fig. 2B and 2C).
(A-C) Con1 replicon cells were incubated with 0.5% ethanol or 20 µM BSO daily for 48 hr±10 µM dipyridyl or 2 mM GSH ester and analyzed for 8-OHG by ELISA (A) or sequenced and analyzed for nucleotide (B) and amino acid substitution rates (C). Data were expressed as fold increase from the control where the control values were 0.122±0.027 ng/ml (n = 6) for panel A, 2.88±0.77×10-4 nt. changes per site for panel B, and 2.80±0.61×10-4 amino acid changes per site for panel C. Letter a indicates statistically significant difference from no inhibitor control. Letters b and c represent statistically significant change from ethanol (no inhibitor) and BSO (no inhibitor), respectively. (D–E) Huh7 cells were transfected with JFH1 RNA and incubated with (D) 0.5% (v/v) ethanol or 20 µM BSO for 48 hrs, or (E) 0.1% (v/v) ethanol or 20 µM BSO±5 µM dipyridyl or 1 mM GSH ester daily for 2 weeks. Then, the samples were analyzed for 8-OHG by ELISA. Data were expressed as fold increase from the control where the control values were 0.106±0.012 and 0.291±0.054 ng/ml for the 48 hr and 2 week time points, respectively. Letters a and b indicate statistically significant difference from the –HCV control and +HCV control, respectively, and c indicates statistically significant difference from respective no inhibitor controls (control no inhibitor, ethanol no inhibitor, and BSO no inhibitor) (n = 4).
HCV increases ROS/RNS in hepatocytes , . Thus, we next examined whether HCV directly induced oxidative RNA damage in the absence of ethanol and BSO. Huh7 cells were transfected with JFH1 RNA that produces infectious virus particles and exposed to 0.5% ethanol (v/v) or 20 µM BSO daily for 48 hrs, or to 0.1% ethanol (v/v) or 20 µM BSO daily for 2 weeks. HCV significantly increased 8-OHG at both time points, and this was exacerbated by ethanol and BSO (Fig. 2D and 2E). Again, dipyridyl and GSH ester could reduce the ethanol-, BSO-, and HCV-induced elevations in 8-OHG (Fig. 2E). HCV core gene also induced a small but statistically significant increase in 8-OHG (Fig. S1B).
Ethanol and BSO increase the propensity for antiviral resistance
Previously, we and others demonstrated that ethanol, at the concentrations used in the present study, potentiates HCV replication while H2O2, BSO, and lipid peroxidation products tend to decrease HCV replication , , , , , , . These findings appeared to contradict the mutagenic effects that ethanol can have on HCV RNA under the same conditions (Table 1). Therefore, we next computed the dn/ds ratio to determine whether sequences were undergoing purifying selection, positive selection, or remained neutral during treatments. The dn/ds ratio of our control group was 0.31, and it increased to 1.05 and 0.72 in the ethanol and BSO groups, respectively (Table 1). Percentage of sites showing positive selection also increased from 4.25% in control group to 12.3% in ethanol and BSO groups (Fig. 3A). Average comparisons of 1,212 genotype 1b sequences in the HCV database revealed that 19.5% of the NS5A-coding region experiences positive selection while about 79% undergoes purifying selection. Dipyridyl and GSH ester could each decrease the percentage of sites undergoing positive selection (Fig. 3A). In addition, dipyridyl reduced the dn/ds ratio of the ethanol group from 1.05 to 0.46 and that of the BSO group from 0.72 to 0.46. The dn/ds ratio of the ethanol group dropped from 1.05 to 0.43, BSO group from 0.72 to 0.21, and control group from 0.31 to 0.24, with GSH ester.
(A) Percentage of sites undergoing positive selection (dn/ds ratio>1) in control, ethanol, and BSO groups. Letter a indicates statistically significant difference from no inhibitor control; b indicates statistically significant difference from respective no inhibitor controls (control no inhibitor, ethanol no inhibitor, and BSO no inhibitor). (B – D) Cumulative synonymous and non-synonymous mutations in control (B), ethanol (C), and BSO (D) groups were plotted against codons via SNAP. Numbers represent NS5A codon number.
Cumulative synonymous and non-synonymous amino acid mutations were also plotted against codons to determine whether mutations clustered at any specific loci (Fig. 3B–3D); vertical steps represent either synonymous or nonsynonymous mutations occurring at that site. As shown in Fig. 3C and 3D, mutations clustered in the C-terminal half of NS5A in ethanol and BSO groups. Sites undergoing positive selection in our study as well as the genotype 1b HCV sequences in the database are mapped in Fig. S2, which shows a greater similarity between the database and our ethanol and BSO treatment groups than between the database and our control group. More specifically, 36.4% of sites undergoing positive selection (dn/ds ratio>1) in our treatment groups were also found to be under positive selection in the database versus 21.1% in the control group. In addition, 36.8% of the sites undergoing positive selection in the HCV database matched sites that underwent positive selection in the ethanol and BSO treatment groups, compared to only 4.6% for the control group. The majority of mutations (97.4%) in our study occurred at sites undergoing positive selection. Synonymous mutations did not increase in the treatment groups (Fig. 3C – D).
Interestingly, some of the amino acid substitutions found in our study were previously associated with antiviral resistance (Table 2). For example, F37L, which enhances the binding of NS5A to 2',5'-oligoadenylate synthetase, occurred in our study with a dn/ds ratio >1 (Fig. 4A). E442G, V279A, F284S, V445A, E442G, V410A, I302V, and S414P, which confer or otherwise were strongly associated with increased resistance to interferon, ribavirin, cyclosporine, and/or Debio 025 could also be identified (Table 2). In addition, Y321N increases resistance to cyclosporine, and all of the nonsynonymous mutations removing tyrosine in our study occurred at this position (Y321C), and Y321C increased the replicative fitness of HCV in the presence of cyclosporine A (Fig. 4B). Ethanol and reactive species also generated mutations in the CD8+ T cell-specific epitopes previously associated with treatment response (Table 2). Other nonsynonymous amino acid substitutions were found in the binding regions for viral and host proteins including double-stranded RNA-activated interferon induced protein kinase and the putative interferon sensitivity determining regions (ISDR). Four sites within the ISDR which, in combinations, enhanced HCV RNA replication in the study by Kohashi et al. had a dn/ds ratio >1 in our study, but no single sequence had more than two amino acid substitutions within ISDR . Amino acid substitutions also occurred in the interferon/ribavirin resistance-determining region (IRRDR) although no single sequence had more than 3 amino acid substitutions within IRRDR .
(A) Structural and functional domains of HCV NS5A . Numbers represent NS5A condon number. (B) Con1(wt) and Con1(Y321C) replicon cells were treated with 1 mM cyclosporine (CsA) for 48 hrs. Total RNA was extracted and HCV RNA was determined. * Indicates a statistically significant difference. (C-D) Location of amino acid substitutions involving serines (C), threonines (D), and tyrosines (D). Putative basal phosphorylation regions are shaded in (A, C, D).
We also found other amino acid substitutions previously reported during in vivo infection of chimpanzees as well as some that may affect the replication rate of HCV (Table 2). Notably, 50.3% of all nonsynonymous mutations in our study either added or removed serine, threonine, or tyrosine (STY) in the treatment groups, versus 9.5% in the control group (P<0.05). Unlike mutations involving threonine which did not show any obvious clustering, the majority of mutations involving serine in domain 3 tended to remove serine, whereas mutations that generated serine were more frequent in domains 1 and 2 (Fig. 4C and 4D). Some of the STY mutations that occurred more frequently and showed positive selection are listed in Table S2. In comparison, STY substitutions constituted 40.1% of all amino acid variations in the genotype 1b NS5A sequences in the database (Fig. S3). S437 (equivalent to S457 of JFH1), hyperphosphorylation sites, and zinc coordination motif were not changed.
RNA viruses are notorious for pronounced sequence variability and high mutation rates that complicate antiviral therapy and development of vaccines. High mutation rate is attributed to the error-prone viral replicase among other variables. In this study, we used HCV, an important hepatotropic human pathogen, plus ethanol, which is often consumed in relatively high quantities and metabolized to generate reactive species and other reactive metabolites in the liver, to examine how these factors affect the genetic variability of an RNA virus. We found that ethanol and BSO can elevate the basal sequence heterogeneity of HCV RNA in hepatocytes within 48 hrs. Agents that decreased the RNA damage could reduce the sequence variability of HCV. Moreover, infectious JFH1 induced RNA damage even in the absence of ethanol and under GSH-sufficient condition, and this was exacerbated by co-incubation with ethanol or BSO. HCV core has been strongly implicated in oxidative stress, and could induce a small increase in 8-OHG in the absence of other viral factors (Fig. S1B). Endogenous sources of ROS/RNS activated by HCV and HCV core are likely to include the mitochondria, hepatocyte NAD(P)H oxidases, inducible nitric oxidase synthase, as well as CYP2E1 , , . In addition, effects of iron chelator suggest a role of an iron-dependent process, such as Fenton reaction, in the oxidative RNA damage. These data suggest that HCV genome variability would be affected by endogenous reactive species and GSH depletion occurring in vivo, and that reactive species’ accelerating the mutation rate is a direct consequence of HCV infection. These factors, therefore, likely contributed to previous estimation of the mutation rate of HCV in patients. In addition, although the overall quasispecies complexity of HCV is expected to be much higher in vivo than in our in vitro study that used a single HCV clone, and the magnitude of increase in sequence variability caused by alcohol is also likely to be higher in vivo (about 4.5% increase with alcohol in reference ) than our in vitro study that showed maximal increase in nt. substitution rate of ∼0.14% (from about 0.03 to 0.17% with ethanol, Table 1) and amino acid substitution rate of ∼0.47% (from about 0.03 to 0.5% with ethanol, Table 1), the effects of ethanol observed in our study may have contributed to the increased heterogeneity of HCV RNA reported with alcohol in the studies by Sherman et al. and Takahashi et al; , . In fact, positive selection data from the HCV sequence database were closer to our treatment groups than the control group (Fig. S2), which is consistent with an important role of GSH depletion and endogenous and exogenous sources of reactive species in viral evolution in vivo. Any differences between our study and the database (Fig. S2) may be attributed to variable exposure to alcohol, lack of complete viral replication cycle in our replicon cell model, diurnal/hormonal/age-dependent fluctuations in GSH, fluctuations in the level of oxidative/nitrosative stress with viral titer and stage of liver disease, and presence of additional selection pressures in vivo.
Our data show that prolonged exposure to low level of ethanol (0.1%, equivalent to 17.2 mM blood alcohol concentration, daily for 2 weeks) could induce RNA damage, as short-term exposure to higher concentration of ethanol (0.5% daily for 48 hrs) also did. Interestingly, prolonged exposure to a low level of ethanol produced less damage than acute exposure to a higher level of ethanol, suggesting that cells adapt to or compensate for chronic repeat exposure to low level of ethanol better than acute exposure to high levels of ethanol. The 0.1% ethanol is approximately the legal limit for drinking under influence in many countries including the U.S.; 0.5% lies in the toxic range but is achieved physiologically, particularly in chronic alcohol users; ethanol is also volatile and the amount metabolized by the cell is significantly less than what is added to cell culture . The concentration of acetaldehyde used in the study also lies within physiological range . These concentrations of ethanol and acetaldehyde did not induce significant cytotoxicity during short-term (48 hr) exposure , but prolonged exposure to 0.5% ethanol was not tolerated well by the cell and could not be continued for 2 weeks. As 20 µM BSO is needed in these cells to achieve the level of GSH depletion seen in hepatitis C patients, the same concentration was used in both short-term and long-term experiments. It is known that 70 – 80% reduction in GSH is generally well-tolerated by cells, and BSO did not produce apparent cytotoxicity in our study.
HCV, like other RNA viruses, operates near error threshold and increasing its mutation rate beyond this threshold can lead to an error catastrophe , . In this study, both ethanol and BSO induced RNA damage but, as mentioned, H2O2 and BSO were previously found to suppress HCV RNA replication through calcium modulation whereas the same concentrations of ethanol elevated HCV replication in these cells and in patients , , , , , , , , , , , . GSH favored HCV replication by countering the suppressive effects of oxidants . While these findings are difficult to reconcile and may appear contradictory, ethanol and oxidative stress/BSO have many effects on the cell, and recently we showed that these seemingly opposite effects of acute ROS/BSO vs. ethanol were explained by other metabolites of ethanol (acetaldehyde, acetate, acetylCoA, and NADH) that had strong lipogenic and therefore favorable effects on HCV that replicates in lipid-rich environment . Furthermore, synonymous mutations did not increase while dn/ds ratio increased with ethanol and BSO treatments in our study. This indicates that mutations we detected were largely due to positive selection. Thus, it is possible that disadvantageous mutations were outcompeted by selection of favorable mutations as the virus adapted to new environment . Indeed, adaptive mutations that affect HCV replication could be detected (Table 2) but nonsense mutations were rare in the study, and it may be speculated that such viral RNAs were outcompeted or eliminated by a process like the nonsense-mediated decay. Importantly, it has also been contested that, under certain conditions, mutagens can impose selection pressure for the development of resistance , . Finally, while ethanol and BSO may affect the replicative fitness of individual sequence variants (Table 2, Table S2), it should be noted that frequency of such mutations were still low, and how some of these mutations modulate NS5A phosphorylation and/or viral replication remains to be tested systematically , , , . Thus, overall effects of ethanol and oxidative stress/BSO on viral replication appears to be more biochemically driven, such as by elevation of cytosolic calcium and NADH/NAD+ and cholesterol content, and the significance of increased sequence heterogeneity may lie in increasing the repertoire of sequence variants to facilitate viral escape and persistence (e.g., when subjected to subsequent antiviral therapy), rather than altering the replicative fitness of HCV genome population as a whole via mutations.
In addition to overall increases in the mutation rate, specific NS5A variants previously implicated in antiviral resistance to interferon, ribavirin, cyclosporine, and Debio 025 could be demonstrated in the study (Table 2 and Table S2). Although the frequency of specific mutations was low, these mutations demonstrate specific changes to the HCV genome that may predispose HCV to antiviral resistance. In terms of the mechanism, some of these mutations were most likely generated randomly but positive selection clearly occurred at many of these sites (Table 2). The mechanism by which ethanol and BSO induced positive selection of specific variants remains unknown. Nonetheless, the data strongly suggest that ethanol, reactive species, and certain antivirals have some shared effects so that adaptation to one can affect resistance to another. Here, it may be noteworthy that H2O2 and BSO have been shown to activate the Jak/Stat pathway in a ligand-independent manner , . Mechanism is likely to involve oxidative modification of protein tyrosine phosphatases and modulation of Jak , . Ethanol and reactive species can also modulate kinases that have been implicated in NS5A phosphorylation as well as antiviral action of cyclosporine A , , , , , , . In addition to positive selection, it should also be noted reactive species can directly modify amino acids, and oxidative stress as well as viral polymerases can induce transitions or transversions depending on the types of reactive species and polymerase involved , , , . Thus, whether the nucleotide substitution trends purely reflect the most common errors produced by HCV replicase plus positive selection/chemical mutagenesis of viral RNA or also other mechanisms, such as direct chemical modification of the viral replicase by reactive species, remains to be tested.
Therefore, in this study, we showed that ethanol and endogenous reactive species can increase the mutation frequency of HCV in hepatoma cells with evidence of positive selection. Positive selection induced by ethanol and GSH depletion may increase the propensity for antiviral resistance. Our data also suggest that agents that decrease oxidative/nitrosative stress may help attenuate the basal mutation rate of HCV as well as positive selection. Clinically, there is increasing evidence that antioxidants or iron depletion can improve the virological response to IFNα-based therapy, and it will be important to study these interactions further using virus-producing systems in vitro as well as in vivo under both short-term and long-term exposure conditions, with the inclusion of other regions of HCV genome also implicated in the antiviral resistance , , , , , , , . Finally, reactive species will modify RNAs as well as DNAs, and oxidative/nitrosative stress is documented in many different virus infections . Thus, it will be interesting to determine whether some of the findings of this study also apply to other viruses and their physicochemical interactions with the environment affecting viral evolution.
Materials and Methods
HCV constructs and cells
Huh7 human hepatoma cell clones supporting continuous replication of a subgenomic HCV replicon RNA of genotype 1b (Con1(S1179I); AJ242652) without forming infectious virions and JFH1 strain (AB047639) that produces infectious virus particles in cell culture were used , . Huh7 cells were initially described by Nakabayashi et al., and our Huh7 cell clone metabolizes ethanol by CYP2E1 , . The in vitro transcription, transfection of the viral RNA, and Huh7 cell culture were performed as described , .
Sequencing and sequence analysis
Total RNAs were collected using Trizol (Invitrogen). Then, the NS5A region (nt. 4612–6013 of Con1 replicon) was reverse transcribed/amplified with AccuScript High Fidelity RT-PCR System (Agilent; reverse transcription error rate is 1.61×10-7, and DNA polymerase error rate is 4.3×10−9). Primer sequences were 5’-ATCAATCGATTGTCTAGAGCTGAAGAGGCTTCACCAG-3’ (reverse) and 5’-GCAATCTTGTACAAGCTTCGCAGCGCATGGCGTGAT-3’ (forward). cDNA products were cloned into pUC19 via HindIII and XbaI sites (underlined) and sequenced at the Joint Genome Institute (Livermore, CA) and University of California Berkeley Sequencing (Berkeley, CA). Sequences were aligned against Con1(S1179I) sequence, using BioEdit/MEGA 4.0 Molecular Evolutionary Genetics Analysis software. Cumulative synonymous and nonsynonymous mutations and dn/ds ratio were computed using Synonymous Nonsynonymous Analysis Program (SNAP; www.hcv.lanl.gov). Amino acid substitution trends were analyzed by position using MutationCounter, a mutation counting program developed for this project, and compared with 1,212 genotype 1b NS5A sequences in the Lawrence Livermore HCV sequence database (www.hcv.lanl.gov). Sequences harboring gaps, undetermined nucleotides, or incomplete sequences were removed prior to the analysis. Sequence data from the Joint Genome Institute and University of California Berkeley Sequencing yielded same conclusions.
Determination of 8-hydroxyguanosine (8-OHG)
RNA samples were analyzed for 8-OHG by ELISA. Briefly, RNA was incubated with 10 U each of DNase I (GE Healthcare), nuclease P1 (SigmaAldrich or US Biological), and alkaline phosphatase (Promega) and analyzed for 8-OHG using RNA Damage Kit (Cell Biolabs, Inc.).
An HCV replicon bearing Y321C was generated by site-directed mutagenesis using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent), and sequence was confirmed by DNA sequencing. Primer sequences were 5′-GCACGCCCGGATTGCAACCCTCCACTG-3′ (forward) and 5′-CAGTGGAGGGTTGCAATCCGGGCGTGC-3′ (reverse).
HCV RNA quantitation
RNA damage in Con1 replicon cells and with HCV core. (A) Con1 replicon cells were incubated with 0.5% ethanol or 20 µM BSO daily for 48 hr with and without 0.1 mM 1,1,4,7,7-diethylenetriaminepentaacetic acid (DETAPAC, an iron chelator), 5 µM pyridoxal isonicotinoyl hydrazone (PIH, an iron chelator), 1 mM NG-methyl-L-arginine acetate (L-NMA, inhibitor of nitric oxide synthase), 40 µM diphenylene iodonium (DPI, inhibitor of flavoproteins such as NAD(P)H oxidases), or 25 µM diallyl disulfide (DADS, inhibitor of CYP2E1). Then, the samples were analyzed for 8-OHG by ELISA, as described. Data were expressed as fold increase from the control where the control value was 0.076±0.026 ng/ml. Letter a indicates statistically significant difference from no inhibitor control, and b indicates statistically significant difference from respective no inhibitor controls (control no inhibitor, ethanol no inhibitor, and BSO no inhibitor) (P<0.05; n = 4). All biochemicals were obtained from SigmaAldrich except PIH, which was synthesized (58–59). (B) Huh7 cells that are transfected with JFH1 core of genotype 2a, Rcp core of genotype 1a, or empty plasmid vector alone were analyzed for 8-OHG by ELISA. * Indicates statistically significant difference from the control.
Sites undergoing positive selection, by group. (A) Location of sites undergoing positive selection in control, ethanol, and BSO groups. Grey lines indicate sites undergoing positive selection that match between this study and the database. Structural and functional domain map of NS5A is drawn approximately to scale. (B) Location of sites undergoing positive selection in control, ethanol, and BSO groups, with and without dipyridyl or GSH ester, and the HCV database. Grey lines indicate sites undergoing positive selection that match between this study and the database.
Position of amino acid variations in the genotype 1b NS5A sequences from database involving serines, threonines, and tyrosines.
Nucleotide substitution trends in control and treatment groups.
The authors thank Monica Medina, Shinichi Sunagawa, and Jennifer Kuehl for assistance with sequencing, Tak Ishikida for programming, and David Ardell and Katherine Harris for assistance with Perl Script. The authors also thank Lindsey Araujo (UC LEEDS Program), Josh Finley, Chieri Ito, Cathy Shijia Li, Wasima Mayer, John Romero (BA STAR Program), Asa Thompson, and Thu Vo for technical assistance, Takaji Wakita for reagents, and Jim Bull, Manel Camps, Henry Jay Forman, and David Ojcius for discussion. Bioinformatics analyses were initiated by an undergraduate student in the context of BIS 142 taught at UC-Merced.
Conceived and designed the experiments: JC. Performed the experiments: SS JM SBP JC. Analyzed the data: SS JM KP MB JC. Wrote the paper: JC. Provided training for data analysis: MB. Obtained permission for use of virus constructs: JC.
- 1. Hofmann WP, Zeuzem S, Sarrazin C (2005) Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 32: 86–91.
- 2. Pawlotsky JM (2003) The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis 16: 587–592.
- 3. Halfon P, Locarnini S (2007) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192–206.
- 4. Zubkova I, Choi YH, Chang E, Pirollo K, Uren T, et al. (2009) T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 27: 2594–2602.
- 5. Duan H, Struble E, Zhong L, Mihalik K, Major M, et al. (2010) Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine 28: 4138–4144.
- 6. Sherman KE, Rouster SD, Mendenhall C, Thee D (1999) Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 30: 265–270.
- 7. Takahashi K, Takahashi T, Takahashi S, Watanabe K, Boku S, et al. (2001) Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non-alcoholic patients. J Gastroenterol Hepatol 16: 416–423.
- 8. Seronello S, Sheikh MY, Choi J (2007) Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic Biol Med 43: 869–882.
- 9. de Mochel NS, Seronello S, Wang SH, Ito C, Zheng JX, et al. (2010) Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology 52: 47–59.
- 10. Kong Q, Lin CL (2010) Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci 67: 1817–1829.
- 11. Kamiya H, Suzuki A, Yamaguchi Y, Handa H, Harashima H (2009) Incorporation of 8-hydroxyguanosine (8-oxo-7,8-dihydroguanosine) 5'-triphosphate by bacterial and human RNA polymerases. Free Radic Biol Med 46: 1703–1707.
- 12. Forman HJ, Cadenas E (1997) Oxidative stress and signal transduction. New York: Chapman & Hall. 475 p.
- 13. Seronello S, Ito C, Wakita T, Choi J (2010) Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem 285: 845–854.
- 14. Choi J, Forman HJ, Ou JH, Lai MM, Seronello S, et al. (2006) Redox modulation of the hepatitis C virus replication complex is calcium dependent. Free Radic Biol Med 41: 1488–1498.
- 15. Barbaro G, Di Lorenzo G, Ribersani M, Soldini M, Giancaspro G, et al. (1999) Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 30: 774–782.
- 16. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, et al. (2004) Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81–89.
- 17. Huang Y, Staschke K, De Francesco R, Tan SL (2007) Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 364: 1–9.
- 18. Rispeter K, Lu M, Behrens SE, Fumiko C, Yoshida T, et al. (2000) Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes 21: 179–188.
- 19. Doreswamy K, Shrilatha B, Rajeshkumar T, Muralidhara (2004) Nickel-induced oxidative stress in testis of mice: evidence of DNA damage and genotoxic effects. J Androl 25: 996–1003.
- 20. Zhang T, Li Y, Lai JP, Douglas SD, Metzger DS, et al. (2003) Alcohol potentiates hepatitis C virus replicon expression. Hepatology 38: 57–65.
- 21. Trujillo-Murillo K, Alvarez-Martinez O, Garza-Rodriguez L, Martinez-Rodriguez H, Bosques-Padilla F, et al. (2007) Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J Viral Hepat 14: 608–617.
- 22. Huang H, Chen Y, Ye J (2007) Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci U S A 104: 18666–18670.
- 23. Kuroki M, Ariumi Y, Ikeda M, Dansako H, Wakita T, et al. (2009) Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. J Virol 83: 2338–2348.
- 24. Kapadia SB, Chisari FV (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102: 2561–2566.
- 25. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, et al. (2006) Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 13: 582–590.
- 26. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48: 38–47.
- 27. Eysseric H, Gonthier B, Soubeyran A, Bessard G, Saxod R, et al. (1997) There is not simple method to maintain a constant ethanol concentration in long-term cell culture: keys to a solution applied to the survey of astrocytic ethanol absorption. Alcohol 14: 111–115.
- 28. Tsukamoto S, Muto T, Nagoya T, Shimamura M, Saito M, et al. (1989) Determinations of ethanol, acetaldehyde and acetate in blood and urine during alcohol oxidation in man. Alcohol Alcohol 24: 101–108.
- 29. Bull JJ, Sanjuan R, Wilke CO (2007) Theory of lethal mutagenesis for viruses. J Virol 81: 2930–2939.
- 30. Domingo E, Gomez J (2007) Quasispecies and its impact on viral hepatitis. Virus Res 127: 131–150.
- 31. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MMC, et al. (2004) Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81–89.
- 32. Sata M, Fukuizumi K, Uchimura Y, Nakano H, Ishii K, et al. (1996) Hepatitis C virus infection in patients with clinically diagnosed alcoholic liver diseases. J Viral Hepat 3: 143–148.
- 33. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, et al. (1994) Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 20: 1115–1120.
- 34. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, et al. (1998) Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27: 1717–1722.
- 35. Romero-Gomez M, Grande L, Nogales MC, Fernandez M, Chavez M, et al. (2001) Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 33: 698–702.
- 36. Sawada M, Takada A, Takase S, Takada N (1993) Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol Suppl 1B: 85–90.
- 37. Carriere M, Rosenberg AR, Conti F, Chouzenoux S, Terris B, et al. (2006) Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption. J Viral Hepat 13: 633–642.
- 38. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ (1996) Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol 25: 821–826.
- 39. Sanjuan R, Cuevas JM, Furio V, Holmes EC, Moya A (2007) Selection for robustness in mutagenized RNA viruses. PLoS Genet 3: e93.
- 40. Pfeiffer JK, Kirkegaard K (2005) Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 79: 2346–2355.
- 41. Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, et al. (2009) Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. Hepatology 50: 678–688.
- 42. Simon AR, Rai U, Fanburg BL, Cochran BH (1998) Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 275: C1640–1652.
- 43. Burlando B, Magnelli V, Panfoli I, Berti E, Viarengo A (2003) Ligand-independent tyrosine kinase signalling in RTH 149 trout hepatoma cells: comparison among heavy metals and pro-oxidants. Cell Physiol Biochem 13: 147–154.
- 44. Lee SR, Kwon KS, Kim SR, Rhee SG (1998) Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 273: 15366–15372.
- 45. Dickinson DA, Forman HJ (2002) Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci 973: 488–504.
- 46. Osada S, Imai H, Tomita H, Tokuyma Y, Okumura N, et al. (2006) Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol 21: 988–993.
- 47. Haviryaji KS, Vemuri MC (1997) Effect of ethanol on nuclear casein kinase II activity in brain. Neurochem Res 22: 699–704.
- 48. Yano M, Ikeda M, Abe KI, Dansako H, Ohkoshi S, et al. (2007) Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture. Antimicrob Agents Chemother 51: 2016–2027.
- 49. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, et al. (2003) Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38: 820–828.
- 50. Svegliati-Baroni G, Ridolfi F, Di Sario A, Saccomanno S, Bendia E, et al. (2001) Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology 33: 1130–1140.
- 51. Lin W, Tsai WL, Shao RX, Wu G, Peng LF, et al. (2010) Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 138: 2509–2518, 2518 e2501.
- 52. Bebenek K, Boyer JC, Kunkel TA (1999) The base substitution fidelity of HIV-1 reverse transcriptase on DNA and RNA templates probed with 8-oxo-deoxyguanosine triphosphate. Mutat Res 429: 149–158.
- 53. Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR (1999) The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 424: 37–49.
- 54. Freistadt MS, Vaccaro JA, Eberle KE (2007) Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol J 4: 44.
- 55. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J (2004) Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266: 37–56.
- 56. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, et al. (1993) N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 13: 279–282.
- 57. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, et al. (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 9: 497–503.
- 58. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, et al. (1998) A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 28: 369–374.
- 59. Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, et al. (1999) Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. Antiviral Res 43: 113–122.
- 60. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, et al. (2000) Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 31: 730–736.
- 61. Gentile I, Viola C, Paesano L, D'Onofrio M, D'Agostino E, et al. (2009) Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 24: 190–196.
- 62. Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, et al. (2011) S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology 140: 830–839.
- 63. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH (2011) S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One 5: e15492.
- 64. Akaike T (2001) Role of free radicals in viral pathogenesis and mutation. Rev Med Virol 11: 87–101.
- 65. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.
- 66. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858–3863.
- 67. Taguchi T, Nagano-Fujii M, Akutsu M, Kadoya H, Ohgimoto S, et al. (2004) Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol 85: 959–969.
- 68. Fernandes F, Ansari IU, Striker R (2010) cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 5: e9815.
- 69. Yang F, Robotham JM, Grise H, Frausto S, Madan V, et al. (2010) A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog 6: e1001118.
- 70. Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, et al. (2010) HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol 53: 50–56.
- 71. Fernandes F, Poole DS, Hoover S, Middleton R, Andrei AC, et al. (2007) Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 46: 1026–1033.
- 72. Noguchi T, Otsubaki T, Ando I, Ogura N, Ikeda S, et al. (2008) Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome. Virology 375: 424–432.
- 73. Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, et al. (2001) Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 121: 1226–1233.
- 74. Hwang DR, Lai HY, Chang ML, Hsu JT, Yeh CT (2005) Emergence of mutation clusters in the HCV genome during sequential viral passages in Sip-L expressing cells. J Virol Methods 129: 170–177.
- 75. Sumpter R Jr, Wang C, Foy E, Loo YM, Gale M Jr (2004) Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol 78: 11591–11604.
- 76. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM (2008) Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 82: 1073–1083.